Literature DB >> 28182434

A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.

Ilse R Dubbelboer1, Elsa Lilienberg1, Erik Sjögren1, Hans Lennernäs1.   

Abstract

Doxorubicin is an anticancer agent, which binds reversibly to topoisomerase I and II, intercalates to DNA base pairs, and generates free radicals. Doxorubicin has a high tissue:plasma partition coefficient and high intracellular binding to the nucleus and other subcellular compartments. The metabolite doxorubicinol has an extensive tissue distribution. This porcine study investigated whether the traditional implementation of tissue binding, described by the tissue:plasma partition coefficient (Kp,t), could be used to appropriately analyze and/or simulate tissue doxorubicin and doxorubicinol concentrations in healthy pigs, when applying a physiologically based pharmacokinetic (PBPK) model approach, or whether intracellular binding is required in the semi-PBPK model. Two semi-PBPK models were developed and evaluated using doxorubicin and doxorubicinol concentrations in healthy pig blood, bile, and urine and kidney and liver tissues. In the generic semi-PBPK model, tissue binding was described using the conventional Kp,t approach. In the binding-specific semi-PBPK model, tissue binding was described using intracellular binding sites. The best semi-PBPK model was validated against a second data set of healthy pig blood and bile concentrations. Both models could be used for analysis and simulations of biliary and urinary excretion of doxorubicin and doxorubicinol and plasma doxorubicinol concentrations in pigs, but the binding-specific model was better at describing plasma doxorubicin concentrations. Porcine tissue concentrations were 400- to 1250-fold better captured by the binding-specific model. This model adequately predicted plasma doxorubicin concentration-time and biliary doxorubicin excretion profiles against the validation data set. The semi-PBPK models applied were similarly effective for analysis of plasma concentrations and biliary and urinary excretion of doxorubicin and doxorubicinol in healthy pigs. Inclusion of intracellular binding in the doxorubicin semi-PBPK models was important to accurately describe tissue concentrations during in vivo conditions.

Entities:  

Keywords:  PBPK; doxorubicin; physiologically based pharmacokinetic modeling; pig

Mesh:

Substances:

Year:  2017        PMID: 28182434     DOI: 10.1021/acs.molpharmaceut.6b00974

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.

Authors:  Alexis Viel; Jérôme Henri; Salim Bouchène; Julian Laroche; Jean-Guy Rolland; Jacqueline Manceau; Michel Laurentie; William Couet; Nicolas Grégoire
Journal:  Pharm Res       Date:  2018-03-12       Impact factor: 4.200

2.  A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.

Authors:  Hua He; Can Liu; Yun Wu; Xinyuan Zhang; Jianghong Fan; Yanguang Cao
Journal:  Pharm Res       Date:  2018-07-09       Impact factor: 4.200

3.  Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment.

Authors:  Ilse R Dubbelboer; Erik Sjögren; Hans Lennernäs
Journal:  AAPS J       Date:  2018-08-30       Impact factor: 4.009

Review 4.  Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma.

Authors:  Charlotte Ebeling Barbier; Femke Heindryckx; Hans Lennernäs
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

5.  Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes.

Authors:  Natalia Pavlovna Akentieva; Natalia Alekseevna Sanina; Artur Rasimovich Gizatullin; Natalia Ivanovna Shkondina; Tatyana Romanovna Prikhodchenko; Stanislav Ivanovich Shram; Nikolai Zhelev; Sergei Michailovich Aldoshin
Journal:  Front Pharmacol       Date:  2019-11-11       Impact factor: 5.810

6.  Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin.

Authors:  George A Mystridis; Georgios C Batzias; Ioannis S Vizirianakis
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.